Morphine, an opioid analgesic commonly prescribed and abused, produces immune-altering effects. Whether morphine's antinociceptive and immunologic effects occur concurrently is unknown. Therefore, we investigated the time course of morphine's immunologic and antinociceptive effects. Rats were given a 15-mg/ kg morphine injection (subcutaneously), and experimental assessments were taken at 30 min, 1 h, 2 h, 6 h, 12 h, and 24 h after treatment. Immune measures included natural killer (NK) cell activity, proliferation of splenic T and B lymphocytes, and cytokine production. Antinociception was assessed by using the tail withdrawal assay. Results show that morphine's immunomodulatory effects on NK cell activity begin within 30 min, continue for at least 12 h, and return to control values by 24 h. In contrast, proliferation of splenic T and B cells and interferon-y production are not altered within 30 min; maximal suppression occurs at 1 h, and recovery begins within 2 h. In all immune measures, therefore, maximal suppression is present at the l-h time point, and recovery is complete within24 h. Morphine induces antinociception 30 min to 2 h after drug administration;
recovery is complete within 6 h. These results suggest the possibility that different mechanisms modulate morphine's immunologic and analgesic effects. Implications:
Acute morphine treatment in rats produces immune alterations and antinociception. Although there are slight differences in morphine's maximal immunological and antinociceptive effects, morphine suppresses immune status at time points concordant with its antinociceptive effects. These effects should be considered when administering morphine to patients whose systems are immunocompromised.
(Anesth Analg 1997;85:620-6) 0 pioid analgesics are used widely, both as very effective pain relievers and, in the case of heroin, as a recreational drug. At a time when acquired immune deficiency syndrome remains a prominent medical problem, this use of the opioids has led to concern regarding their effects on the normal functioning of the immune system. Recent studies in rodents reveal the specificity and complexity of morphine's effects on the immune system. For example, an acute systemic injection of morphine decreases the proliferation of T cells to mitogen stimulation in both splenic (1,2) and blood (l-4) lymphocyte populations as well as the proliferation of B-cell splenic lymphocytes (1,2). Acute morphine treatment also decreases natural killer (NK) cell activity (1,3,5-7), macrophage-mediated inhibition of tumor-cell proliferation (8), phagocytosis (8), killing activity of polymorphonuclear cells (S), and production of interferon-y (IFN-y) (1,9), interleukin 2 (1), and antibody (10). Although these results indicate that opioids such as morphine can certainly alter immune function, differences in morphine's time course of effects are reported across laboratories. For example, Lysle et al. (1) report that morphine decreases the T-cell proliferation of splenic lymphocytes one hour after administration, whereas Bayer et al. (3,5) report no differences in lymphocyte proliferation two hours after administration. In contrast, morphine decreases T-cell proliferation of blood lymphocytes at both one hour (1) and two hours (3,5). These data suggest at least two possibilities: that splenic lymphocytes are less sensitive to morphine treatment than blood lymphocytes (3) or that morphine's effects are time-dependent. In fact, splenic lymphocytes may be more sensitive to acute morphine treatment and therefore be suppressed at earlier time points than blood lymphocytes.
The cytotoxic activity of NK cells also reveals differential findings across time points. Studies have found that morphine suppresses NK cell activity 1, 2, 01997 by the International Anesthesia Research Society 0003.2999/97/$5.00 and 3 hours after administration (1,3,5-7); however, NK activity returns to normal after 12 (5) and 24 hours (5,7). In contrast, Pacifici et al. (9) found that morphine did not suppress NK cell activity when tested 20 minutes, 40 minutes, 2 hours, and 24 hours after administration.
To examine this time dependency further, we assessed the immunologic effects of an acute injection of morphine. Rats were injected with either saline or a dose of morphine (subcutaneously) known to produce maximal immune alterations (15 mg/ kg) (1) at different times. To replicate and extend current findings in the literature, in our first experiment, we killed rats 1, 6,12, or 24 hours after morphine administration in our first experiment. Results from these time points led us to refine further the onset and recovery of morphine's effects, with rats being killed either 30 minutes, 1 hour, 2 hours, or 6 hours after treatment.
Studies have suggested that morphine's immunomodulatory effects may be mediated via mechanisms similar to morphine's antinociceptive effects. For example, Yaksh et al. (11) found that microinjections of morphine into the mesencephalic periaqueductal gray (PAG) produce analgesia, whereas Weber and Pert (12) reported that microinjections into the PAG suppress NK cell activity. Thus, we sought to determine whether the time course of morphine's effects on immune function was similar to that of morphine's antinociceptive effects. Given the therapeutic use of morphine for pain relief, such a comparison has important clinical relevance.
Methods
Our institution's animal care and use committee approved all procedures used in this experiment. Male Lewis rats 65-70 days old and 250-300 g in weight were purchased from Charles River Laboratories (Raleigh, NC). Upon arrival, rats were housed individually in wire mesh cages in a temperature-and humidity-controlled colony room and maintained on an artificially illuminated reversed light-dark cycle (12 h) with lights on at 4:00 AM. The rats received a 2-wk period to adjust to the home-cage environment and were handled twice before the experiment. Food (rat chow) and water were provided ad Zibitum throughout the habituation period.
Morphine sulfate (National Institutes on Drug Abuse, Rockville, MD) was prepared in 0.9% saline to a concentration of 15 mg/mL. Rats were injected with 15 mg/kg morphine or an equal volume of the 0.9% saline vehicle. Drugs were administered via subcutaneous injections into the lower lateral abdomen.
Rats were killed rapidly by cervical dislocation. Spleens were removed and placed in 7 mL of RPMI-1640 supplemented with 10 mM 4-(2-hydroxyethyl)-lpiperaineethanesulfonic acid, 2 mM glutamine, and 50 pg/mL gentamicin (GIBCO BRL, Grand Island, NY; hereafter referred to as supplemented RPMI). Spleens were ground between two sterilized frosted slides to single cell suspensions in supplemented RPM1 enriched with 10% fetal bovine serum (GIBCO; hereafter referred to as complete RPMI) and counted using a NOVA Celltrack II cell analyzer. Splenocyte suspensions were adjusted with complete RPM1 to a density of 5 X lo6 leukocytes per milliliter and immediately used for immune assays.
The procedures for the splenic NK cell assay have been described in detail elsewhere (13). Briefly, adjusted splenocyte suspensions were used as a source of effector cells, and a murine T-cell lymphoma, YAC-1 (American Type Cell Collection, Rockville, MD), was used as a source of target cells. The YAC-1 cells were labeled by incubation with 200 &i of sodium chromate-51 (DuPont-New England Nuclear, Boston, MA). Microtiter plates containing effector / target ratios of lOO:l, 50:1, 25:1, and 12.5:1 were used in the assay. After a 5-h incubation at 37'C in a humidified CO, incubator, the microtiter plates were centrifuged, and the amount of sodium chromate-51 released in the supernatant was determined using an LKB gamma counter (Model 1272 CliniGamma; Wallac, Gaithersburg, MD). Lytic units were calculated with a computer program, based on the equations of Press and Maroun (14).
Mitogen stimulation assays were completed using the adjusted splenocyte suspension. B-cell lymphocyte proliferation was stimulated with the mitogen lipopolysaccharide (LPS; Difco, Detroit, MI). T-cell lymphocyte proliferation was stimulated with the mitogen concanavalin A (Con-A; Sigma Chemical Company, St. Louis, MO) and the superantigen toxic shock syndrome toxin-l (TSST-1; Sigma Chemical Company). Superantigens, unlike mitogens, activate a large proportion of T cells by binding outside the cleft of the major histocompatibility complex class II molecule and have been shown to play a role in a number of disease processes (15). Adjusted splenocyte suspensions (100 pL) were pipetted in triplicate into microtiter plates (Costar 3595; Costar, Cambridge, MA) containing final concentrations of 0, 0.5, and 5.0 pg/mL Con-A and LPS, and 0, 0.05, 0.5, and 5.0 pg/ mL TSST-1. The cultures were pulsed with 1 &i of [3H]thymidine (specific activity 6.7 Ci/mM; ICN Biomedical Inc., Irvine, CA) during the last 5 h (Con-A and LPS; Wallac) or 18 h (TSST-1; Wallac) of incubation. Con-A and LPS cultures were incubated for 48 h, and TSST-1 cultures were incubated for 72 h. A Tomtec automatic 96 well cell harvester was used to harvest the cultures and a Wallac liquid scintillation counter (model 1205) was used to measure the amount of [3H]thymidine incorporated into the cells.
The amount of IFN-7 produced in Con-Astimulated splenocyte cultures was measured using a commercial enzyme-linked immunosorbent assay kit (GIBCO BRL). Adjusted splenocyte suspensions were pipetted into microtiter plates, and the cultures were stimulated with 0 or 5.0 pg/ mL Con-A for 48 h at 37°C in a humidified 5% CO, incubator and then stored at -80°C until completion of the assay. On the day of the assay, samples were thawed and centrifuged. Supernatants were collected, and the enzyme-linked immunosorbent assay was conducted on duplicate samples according to the protocol provided by the manufacturer. Absorbances were determined with a microtiter plate reader (model EL312; Biotek, Winooski, VT), and the amount of IFN-JJ present in each sample was determined using a standard curve derived from pure recombinant rat IFN.
Rats were acclimated to the tail withdrawal procedure 30 min before initiation of the experiment by placing the rat's tail in a beaker filled with tepid water. At the beginning of the assay, rats were held vertically above a 52°C water bath, and their tails were lowered into the water. The trial was terminated when the rat removed its tail from the water or at the predetermined cutoff of 15 s. Immediately after collection of baseline latencies, morphine was injected, and tail withdrawal latencies were collected at the appropriate NK cell activity, proliferation data, and IFN-y production were assessed using one-way analysis of variance with time as the independent variable. To determine when suppression occurred, planned contrasts compared data from each time point with control rats. The data from saline-injected rats did not differ across the time points; therefore, data from these rats were combined to create a single control group for each manipulation. To investigate recovery, we completed planned contrasts compared data from morphinetreated rats at each time point with control rats [previous studies in our laboratory show that suppression occurs at 1 h (5)] when the morphine-treated rats were different from saline controls. All proliferation data are presented at optimal concentrations.
Percent maximal antinociception was assessed using a two-way analysis of variance, with treatment representing the between-groups factor and time representing the repeated measure. Planned contrasts were completed at each time point to determine whether morphine-treated animals differed from saline-injected animals. All analyses were conducted with an 01 level set at 0.05.
Results
In general, 15 mg/ kg morphine suppressed NK cell activity, proliferation of splenic T and B cells, and IFN-y production 1 h after administration. Recovery of T and B cells and IFN-7 production began within 2 h, whereas NK cell activity did not recover until 24 h after administration. Analysis of variance of NK cell activity revealed a significant main effect of time: F (4,15) = 12.87, P < 0.001 (Figure 1 ). Planned contrasts showed that NK activity was decreased in rats killed 1,6, and 12 h after morphine administration (P < 0.002) when compared with rats injected with saline. Rats killed 24 h after morphine administration did not differ from control animals (P = not significant [NS]).
Analysis of proliferation to the T-cell mitogen Con-A revealed a significant main effect of time: F (4,15) = 3.99, P < 0.03 (Figure 2A) . Compared with saline, morphine reduced T-cell proliferation 1 h after administration (P < 0.003); however, proliferation was no longer suppressed 6, 12, and 24 h after treatment PW Similar results occurred when proliferation was measured in response to the superantigen TSST-1. Analysis of variance revealed a main effect of time: F Figure 2B ). Morphine and saline treated rats did not differ 6, 12, and 24 h after administration (P = NS). Analysis of proliferation to the B-cell mitogen LPS revealed a main effect of time: F (4,15) = 3.22, P < 0.05 ( Figure 2C ). Maximal suppression occurred 1 h after morphine administration (P < 0.02). There were no differences between the morphine-and saline-treated rats killed 6, 12, and 24 h after administration (P = NS).
Analysis of IFN-y production revealed a marginally significant time effect: F (4,15) = 2.53, P < 0.09, with production maximally decreased 1 h after morphine administration (P < 0.02) ( Figure 2D ). There were no differences between the morphine-and saline-treated rats killed 6, 12, and 24 h after administration (P = NS).
In general, morphine's immunomodulatory effects occur within 30 min for NK cell activity and within 1 h for proliferation of T and B cells and IFN-7 production. NK cell activity did not recover by 6 h, whereas T-and B-cell proliferation and IFN-y production began marginal recovery within 2 h.
Analysis of NK cell activity revealed a main effect of time: F (4,35) = 6.96, P < 0.001 (Figure 3) . Compared with saline, morphine decreased NK cell activity 30 min to 6 h after administration (P < 0.001). Planned contrasts with the l-h time point show that recovery did not begin within 6 h (P = NS).
Analysis of T-cell proliferation to Con-A revealed a main effect of time: F (4,35) = 6.96, P < 0.001 ( Figure  4A ). Although morphine did not significantly reduce proliferation by 30 min, maximal suppression occurred within 1 h (P < O.OOl), remained present after 2 h (P < O.Ol), and decreased by 6 h (P = NS). Planned contrasts with the l-h time point suggest that recovery began within 2 h (P < 0.07) and reached significance by 6 h (P < 0.004). [pIAnalysis of proliferation to the superantigen TSST-1 revealed a main effect of time: F (4,35) = 7.73, P < 0.001 (Figure 418 ). Morphine produced no immunealtering effects by 30 min (P = NS). However, suppression occurred within 1 h (P < 0.001) and remained present after 2 h (P < 0.02) and 6 h (P < 0.03). Planned contrasts suggest that recovery began within 2 h (P < 0.06) and reached significance by 6 h (P < 0.03). Although T-cell proliferation began to return to control levels within 2 h, complete recovery did not occur within 6 h.
Analysis of proliferation to LPS revealed a main effect of time: F (4,35) = 6.41, P < 0.001 ( Figure 4C ). Once again, no effects were present within 30 min (P = NS). Proliferation was significantly suppressed at 1 h (P < 0.001) and remained marginally suppressed after 2 and 6 h (P < 0.06 and P < 0.07, respectively). Recovery from maximal suppression began to occur within 2 h (P < 0.02). Although B-cell proliferation began to return to control levels within 2 h, complete recovery did not occur within 6 h.
Analysis of IFN-7 production revealed a significant effect of time: F (4,35) = 17.39, P < 0.001 ( Figure 4D ). Although morphine did not reduce cytokine production within 30 min (P = NS), maximal suppression occurred within 1 h (P < O.OOl), remained present up to 2 h (P < 0.003), and decreased by 6 h (P = NS). Planned contrasts with the l-h time point showed that recovery began within 2 h (P < 0.03) and was complete within 6 h.
Antinociception measurements in Experiment 2 after morphine administration resulted in a significant treatment by time interaction: F (5,90) = 46.53, P < 0.001 ( Figure 5 ). Analysis also indicated significant main effects of treatment: F (1,lS) = 62.94, P < 0.001, and time: F (5,90) = 62.26, P < 0.001. Saline-injected rats exhibited no antinociception across all time points, whereas morphine-injected rats showed a peak of 70% maximal antinociception within 30 min Morphine Exposure (Hrs) Figure  5 . Tail withdrawal latencies of rats transiently increased after an injection of 15 mg/kg morphine (n = 10 for each treatment group).
Solid bars represent morphine-treated rats, and striped bars represent saline-treated rats.
after administration (P < 0.01); the antinociception remained present at 1 h (P < 0.01) and 2 h (P < 0.01) but was no longer evident from 6 to 24 h (P = NS).
Discussion
The present study suggests that morphine's immunologic and analgesic effects follow a similar time course in that both effects are maximally present at 1 h and recovered within 24 h. However, one dissimilarity is that morphine's suppression of NK cell activity begins within 30 minutes, continues for 12 h, and recovers by 24 h. In contrast, morphine's effects on the proliferation of splenic T and B cells and IFN-7 production begins at 1 h, with initiation of recovery occurring within 2 h. Finally, morphine's antinociceptive effects begin within 30 min, remain present for 2 h, and recover within 6 h.
The present study supports previous findings in our laboratory showing that morphine suppresses NK cell activity, splenic T-and B-cell proliferation, and IFN-y production 1 h after treatment (1). The results from this study extend previous findings regarding the duration of morphine's immunomodulatory effects and provide clarification to the literature. For example, Bayer et al. (3,5) report suppression of NK cell activity, but not splenic T cell proliferation, 2 h after morphine administration.
Our current findings indicate that morphine suppresses NK cell activity for 12 h after administration;
however, proliferation of splenic T and B cells follows a time course whereby the 2-h time point represents a transition point between maximal suppression and recovery. Therefore, it seems that time is a variable that must be considered when evaluating morphine's immunomodulatory effects. The differential time-dependent effects of morphine treatment on the various subsets of immune function suggest that NK cell activity and proliferation of T and B cells, as well as IFN-y production, are mediated by different mechanisms.
In fact, studies in our laboratory have shown that morphine's suppression of splenic T-and B-cell proliferation to stimulation by Con-A and LPS involves sympathoadrenal activity, whereas morphine's suppressive effect on IFN-y involves sympathetic, but not adrenal, activity (13). In addition, NK cell activity involves neither sympathetic nor adrenocortical activity (4,13). Therefore, the time course of morphine's suppressive effects on immune subsets may be due to regulation via different mechanisms.
An additional hypothesis can be made based on findings that reveal that specific neural structures are involved in subsets of morphine-induced immune alterations.
For example, morphine infused into the PAG suppresses NK activity (12, 16) but has no effect on splenic T lymphocyte proliferation (16). These data suggest that the time course of morphine's effects may differ across immune measurements due to the involvement of separate brain regions.
The divergence of morphine's immunologic and analgesic time course effects observed in the present study may also be due to modulation by different neural structures.
For example, morphine infused into the anterior hypothalamus alters responsiveness of blood lymphocytes to mitogen stimulation without producing antinociception (4). These findings suggest that morphine's immunologic and analgesic effects also may be modulated by different mechanisms.
The widespread use of morphine in clinical settings as a pain reliever creates a concern when considering the fact that morphine produces immunomodulatory effects at a time point concordant with morphine's analgesic effects. These effects should be considered when administering morphine to patients whose systems are immunocompromised.
Further clarification of the mechanisms responsible for morphine's immunologic and analgesic effects would provide beneficial information for clinical populations.
